Proteomic profiling of chordoma

Journal of Surgical Oncology

Volumn 102, Issue 7, 2010, Pages 719-

  DeLaney, Thomas F ^a   Duan, Zhenfeng ^a   Hornicek, Francis J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

CANCER RECURRENCE; CHORDOMA; DISEASE FREE SURVIVAL; EDITORIAL; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEOMICS; UPREGULATION;

CHORDOMA; HUMANS; NEOPLASM PROTEINS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 78649677616     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21766     Document Type: Editorial

References (5)

1. Patterson SD, Aebersold RH,: Proteomics: The first decade and beyond. Nat Genet 2003; 33: 311-323.
2. Scheil S, Bruderlein S, Liehr T, et al.: Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 2001; 32: 203-211.
3. Stacchiotti S, Casali PG, Lo Vullo S, et al.: Chordoma of the mobile spine and sacrum: A retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 2009; 17: 211-219.
4. DeLaney TF, Liebsch NJ, Pedlow FX, et al.: Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys 2009; 74: 732-739.
5. Stacchiotti S, Marrari A, Tamborini E, et al.: Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol 2009; 20: 1886-1894.